{"DataElement":{"publicId":"2421091","version":"1","preferredName":"Hormone Therapy Gonadotropin-Releasing Hormone Analog Administered Type","preferredDefinition":"the type of GnRH analog administered.","longName":"HORM_GNRHA_ADM_TP","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2744052","version":"1","preferredName":"Hormone Therapy Gonadotropin-Releasing Hormone Analog Administered","preferredDefinition":"information related to use of a synthetic agent that manipulates luteinizing and follicle stimulating hormones and eventually decreases gonadal hormones involved in hormone-dependent cancers activity for therapeutic purposes not specified for a clinical trial.","longName":"HORMTX_GRHA_ADMIN","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2433915","version":"1","preferredName":"Hormone Therapy","preferredDefinition":"Various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level. The treatment may include administration of hormones or hormone analogs to the patient, or decreasing the level of hormones in the body by using hormone antagonists, or hormone ablation therapy. The concept covers but not limited to: intermittent or permanent hormone suppression or ablation in treatment of hormone-dependent tumors, hormone replacement therapy of any kind, hormonal component of gender reassignment therapy, hormonal contraception, surgical and radiation castration.","longName":"C15445","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hormone Therapy","conceptCode":"C15445","definition":"Various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"06674CCB-CDA8-04A9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-28","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-28","modifiedBy":"ONEDATA","dateModified":"2005-11-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2468991","version":"1","preferredName":"Gonadotropin-Releasing Hormone Analog Administered","preferredDefinition":"(LOO-tin-eye-zing.AG-o-nist) LH-RH agonist.  A drug that inhibits the secretion of sex hormones.  In men, LH-RH agonist causes testosterone levels to fall.  In women, LH-RH agonist causes the levels of estrogen and other sex hormones to fall.:Given.","longName":"C2022:C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gonadotropin-Releasing Hormone Analogue","conceptCode":"C2022","definition":"A hormone made in the laboratory that has the same effect as the gonadotropin-releasing hormone (GnRH) produced naturally by the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"10A20F23-F943-05C3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-04","endDate":null,"createdBy":"PWEST","dateCreated":"2006-04-04","modifiedBy":"ONEDATA","dateModified":"2006-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4B8A9BDA-5D77-6D62-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-04-23","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2421090","version":"1","preferredName":"Gonadotrophin Releasing Hormone Administered Type","preferredDefinition":"the type of GnRH analog administered.","longName":"GNRH_ADMIN_TP","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"20","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Triptorelin","valueDescription":"TRIPTORELIN","ValueMeaning":{"publicId":"2563644","version":"1","preferredName":"TRIPTORELIN","longName":"2563644","preferredDefinition":"TRIPTORELIN","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Triptorelin","conceptCode":"C1267","definition":"A synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH).  Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous administration, this agent effects sustained decreases in LH and FSH production and testicular and ovarian steroidogenesis. Serum testosterone concentrations may fall to levels typically observed in surgically castrated men. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C5A9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-12-05","endDate":null,"createdBy":"CVALMONT","dateCreated":"2002-12-05","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"03668B75-85D6-19AE-E044-0003BA3F9857","beginDate":"2005-10-18","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"ONEDATA","dateModified":"2005-10-18","deletedIndicator":"No"},{"value":"Decapeptyl","valueDescription":"Decapeptyl","ValueMeaning":{"publicId":"2576624","version":"1","preferredName":"Decapeptyl","longName":"2576624","preferredDefinition":"A drug that is used to treat advanced prostate cancer, and is being studied in the treatment of breast cancer. It belongs to the family of hormonal drugs called gonadotropin-releasing hormone analogs.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Triptorelin","conceptCode":"C1267","definition":"A synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH).  Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous administration, this agent effects sustained decreases in LH and FSH production and testicular and ovarian steroidogenesis. Serum testosterone concentrations may fall to levels typically observed in surgically castrated men. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F85D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-18","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"COOPERM","dateModified":"2016-08-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"03668B75-85DA-19AE-E044-0003BA3F9857","beginDate":"2005-10-18","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"ONEDATA","dateModified":"2005-10-18","deletedIndicator":"No"},{"value":"Trelstar Depot","valueDescription":"Trelstar Depot","ValueMeaning":{"publicId":"2576625","version":"1","preferredName":"Trelstar Depot","longName":"2576625","preferredDefinition":"Trelstar Depot","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F85E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-18","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"SHIDED","dateModified":"2005-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"03668B75-85DE-19AE-E044-0003BA3F9857","beginDate":"2005-10-18","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"ONEDATA","dateModified":"2005-10-18","deletedIndicator":"No"},{"value":"Goserelin","valueDescription":"GOSERELIN","ValueMeaning":{"publicId":"2563645","version":"1","preferredName":"GOSERELIN","longName":"2563645","preferredDefinition":"GOSERELIN","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Goserelin","conceptCode":"C1374","definition":"A synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH) with antineoplastic activity. Goserelin binds to and activates pituitary gonadotropin releasing hormone (GnRH) receptors. Prolonged administration of goserelin inhibits the secretion of pituitary gonadotropin, thereby decreasing levels of testosterone (in males) and estradiol (in females).  Administration of this agent in a depot formulation may result in the regression of sex hormone-sensitive tumors and a reduction in sex organ size and function. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C5AA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-12-05","endDate":null,"createdBy":"CVALMONT","dateCreated":"2002-12-05","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"03668B75-85E1-19AE-E044-0003BA3F9857","beginDate":"2005-10-18","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"ONEDATA","dateModified":"2005-10-18","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2567790","version":"1","preferredName":"Other","longName":"2567790","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D5DB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"KUMMEROA","dateModified":"2023-11-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"03668B75-85E4-19AE-E044-0003BA3F9857","beginDate":"2005-10-18","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"ONEDATA","dateModified":"2005-10-18","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2177853","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"Type","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C16D625D-02B6-1907-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-07-09","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-07-09","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"IBCSG CRF:International Breast Cancer Study Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"03677B08-5FD5-1C11-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-18","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"SBR","dateModified":"2008-12-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811831","version":"1","longName":"Breast","context":"CTEP"}]},{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811963","version":"1","longName":"Treatment","context":"CTEP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"CRF Text","type":"Preferred Question Text","description":"Agent Name","url":null,"context":"CTEP"}],"origin":"IBCSG CRF:International Breast Cancer Study Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"03677D9E-B6BB-19B8-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-18","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"CAMPBELB","dateModified":"2008-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}